Foghorn Therapeutics swings to Q3 2026 net income of $58.2 million

• Foghorn Therapeutics swung to third-quarter 2026 net income of $58.2 million from a $15.8 million loss a year earlier.
• Collaboration revenue rose to $83.5 million, driven by a $74.1 million cumulative catch-up adjustment primarily related to updated estimated future costs.
• Cash, cash equivalents, and marketable securities totaled $156.2 million at September 30, providing runway into the second half of 2029.
• First-in-human trials for its oral inflammatory bowel disease program could begin by the end of 2027.
• The selective EP300 degrader program targets an IND in 2027, focusing on multiple myeloma and diffuse large B-cell lymphoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foghorn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-071871), on November 09, 2026, and is solely responsible for the information contained therein.